V1RB7 Inhibitors
V1RB7 inhibitors encompass a range of chemical compounds that indirectly influence the function of V1RB7 through various biochemical pathways. For instance, aripiprazole, a dopamine D2 receptor partial agonist, can modulate dopaminergic signaling, which may indirectly affect V1RB7 by altering the neurotransmitter environment that V1RB7 operates within. Similarly, buspirone acts on the serotonin pathway as a 5-HT1A receptor partial agonist, potentially affecting the cAMP levels that might modulate V1RB7 function. Olanzapine and haloperidol are antipsychotics with a common trait of antagonizing D2 receptors, which could lead to reduced cAMP production, thereby influencing V1RB7 signaling if it is cAMP-dependent. Losartan, targeting angiotensin II signaling, and propranolol, an adrenergic antagonist, both have the potential to modulate GPCR-related pathways that V1RB7 may be part of, resulting in an indirect reduction ofV1RB7 activity.
The spectrum of V1RB7 inhibitors is further diversified with compounds that affect endocrine signaling, which could have downstream effects on V1RB7. Ketoconazole's inhibition of cytochrome P450 enzymes may alter steroid hormone biosynthesis, thus potentially impacting V1RB7 activity if it is sensitive to steroid levels. Raloxifene, acting as a selective estrogen receptor modulator, could modify estrogenic action and thereby influence V1RB7 signaling indirectly. Additionally, yohimbine and alprenolol, by modulating adrenergic pathways, might affect V1RB7 function through changes in neurotransmitter release and cAMP levels, respectively. Compounds like nicotine and atropine target cholinergic receptors and could alter V1RB7 activity by influencing the neural circuits in which V1RB7 may be involved. Each of these inhibitors works through distinct pathways, yet converges on the potential to modulate V1RB7 activity either through changes in neurotransmitter systems, hormonal levels, or second messenger dynamics, exemplifying the complex nature of cellular signaling and the indirect mechanisms through which V1RB7 activity can be inhibited.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aripiprazole | 129722-12-9 | sc-207300 sc-207300A sc-207300B | 100 mg 1 g 5 g | $179.00 $212.00 $1037.00 | 3 | |
Aripiprazole is a dopamine D2 receptor partial agonist. V1RB7, being a G-protein coupled receptor, may be affected by changes in dopamine levels due to aripiprazole's modulatory effect on D2 receptor signaling, potentially altering V1RB7 signaling. | ||||||
Olanzapine | 132539-06-1 | sc-212469 | 100 mg | $133.00 | 6 | |
Olanzapine is an atypical antipsychotic with affinity for various neurotransmitter receptors. It may inhibit cAMP production by antagonizing D2 receptors, which could indirectly impact V1RB7's cAMP-dependent signaling. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol is a potent dopamine D2 receptor antagonist. By blocking dopamine signaling pathways, haloperidol could indirectly inhibit V1RB7 if V1RB7 signaling is modulated by dopamine levels. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan is an angiotensin II receptor antagonist. It inhibits the AT1 receptor, potentially altering angiotensin signaling pathways that could cross-talk with V1RB7-mediated pathways, leading to an indirect inhibition of V1RB7. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective beta-adrenergic receptor antagonist. By inhibiting adrenergic signaling, it could decrease cAMP levels in cells, which may indirectly affect V1RB7 activity if V1RB7 is coupled to Gs proteins. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole inhibits cytochrome P450 enzymes, which could lead to altered steroidogenesis. Since V1RB7 could be modulated by steroid hormones, ketoconazole might influence V1RB7 activity through this indirect mechanism. | ||||||
Raloxifene | 84449-90-1 | sc-476458 | 1 g | $802.00 | 3 | |
Raloxifene acts as a selective estrogen receptor modulator (SERM). Its influence on estrogen receptor signaling could indirectly affect V1RB7 if there is interplay between estrogen signaling and V1RB7 function. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Yohimbine is an alpha-2 adrenergic receptor antagonist. It could increase neurotransmitter release, affecting noradrenergic signaling that may indirectly modulate V1RB7 activity if V1RB7 is sensitive to changes in this pathway. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
Atropine is a competitive antagonist for the muscarinic acetylcholine receptors. It could alter parasympathetic nerve signaling, potentially affecting V1RB7 indirectly if V1RB7 is involved in related pathways. | ||||||
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Alprenolol is a non-selective beta-adrenergic receptor antagonist, similar to propranolol. It may also reduce cAMP levels, affecting V1RB7 activity indirectly if V1RB7 is coupled to Gs proteins that respond to cAMP. | ||||||